To help kick off 2016, we wanted to bring you an update on a couple of exciting trials in PSC that are currently enrolling patients.
There are several medications currently in Phase 2 clinical trials with indications for the treatment of PSC. One of these trials is being done by Intercept Pharmaceuticals evaluating a medication called Obeticholic Acid (OCA). “This study in PSC will also evaluate OCA’s effect on liver biochemistry, including alkaline phosphatase (ALP), and safety. Patients in the trial will receive obeticholic acid or a placebo for 24 weeks during the trial, to see if OCA improves ALP in patients with PSC, versus the placebo alone.”
Once this phase of the trial has been completed, they will also begin a longer study to determine the long-term safety of the medication.
Another medication making its way into clinical trials for PSC is made by Tobira Therapeutics. This medication is called Cenicriviroc (CVC).
“CVC is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways that cause liver damage and often lead to cirrhosis, liver cancer or liver failure. Tobira believes this novel approach will establish CVC as both a single-agent and as a cornerstone treatment in multi-therapy regimens for NASH, PSC and other liver disease.” (https://www.streetaccount.com/pressrelease.aspx?ticker=TBRA&intraday_id=1835954)
Look for updates on additional clinical trials soon and stay up-to-date on trials relevant to PSC by joining PSCAmerica here.